153 research outputs found
Recommended from our members
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases : a Two-Stage, Multicenter, Prospective, Open-Label Study
PurposeTo assess the efficacy and safety of panzyga® (intravenous immunoglobulin 10%) in preventing serious bacterial infections (SBIs) in patients with primary immunodeficiency diseases (PIDs), a prospective, open-label, multicenter, phase 3 study and an open-label extension study were undertaken.MethodsInitially, the study drug (infusion rate ≤0.08 mL/kg/min) was administered at intervals of 3 or 4 weeks for 12 months, followed by 3 months of panzyga® at infusion rates increasing from 0.08 to 0.14 mL/kg/min. The primary endpoint in the main study was the rate of SBIs per patient-year on treatment. Secondary outcomes included non-serious infections, work/school absence, episodes of fever, quality of life, and adverse events (AEs).ResultsThe main study enrolled 51 patients (35% female, mean age 26.8 years), with 21 participating in the extension study. The rate of SBIs per patient-year was 0.08 in the total population; there were four SBIs in the 4-weekly treatment group (2/30 patients) and none in the 3-weekly group (n = 21). Compared with 4-weekly treatment, 3-weekly treatment was associated with a higher rate of upper respiratory tract infections (RTIs), ear infections, and work/school absences, but a lower rate of lower RTIs and fever. Treatment was generally well tolerated; no AE led to treatment withdrawal or death.ConclusionsOverall, the use of panzyga® in patients with antibody-deficient PID was associated with a low rate of AEs and was effective in preventing SBIs, exceeding US FDA and European Medicines Agency recommendations for efficacy
Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID)
Background: There are inconsistent data on the risk factors for Clostridium difficile infection (CDI) in the literature.
Aims: To use two C. difficile infection (CDI) case-control study groups to compare risk factors in hospitalized patients with diarrhea across different countries.
Methods: A multi-center group of CDI cases/controls were identified by standardized testing from seven countries from the prior EUropean, multi-center, prospective bi-annual point prevalence study of CLostridium difficile Infection in hospitalized patients with Diarrhea (EUCLID). A second group of CDI cases/controls was identified from a single center in Germany [parallel study site (PSS)]. Data were extracted from the medical notes to assess CDI risk factors. Univariate analyses and multivariate logistic regression models were used to identify and compare risk factors between the two groups.
Results: There were 253 and 158 cases and 921 and 584 controls in the PSS and EUCLID groups, respectively. Significant variables from univariate analyses in both groups were age ≥65, number of antibiotics (OR 1.2 for each additional antibiotic) and prior hospital admission (all p < 0.001). Congestive heart failure, diabetes, admission from assisted living or Emergency Department, proton pump inhibitors, and chronic renal disease were significant in PSS (all p < 0.05) but not EUCLID. Dementia and admitted with other bacterial diseases were significant in EUCLID (p < 0.05) but not PSS. Following multivariate analyses, age ≥ 65, number of antibiotics and prior hospital admission were consistently identified as CDI risk factors in each individual group and combined datasets.
Conclusion: Our results show that the same CDI risk factors were identified across datasets. These were age ≥ 65 years, antibiotic use and prior hospital admission. Importantly, the odds of developing CDI increases with each extra antibiotic prescribed
a pilot study, 2013
Introduction After recognition of European outbreaks of Clostridium difficile
infections (CDIs) associated with the emergence of PCR ribotype 027/NAP1 in
2005, CDI surveillance at country level was encouraged by the European Centre
for Disease Prevention and Control (ECDC) [1]. In 2008, an ECDC-supported
European CDI survey (ECDIS) identified large intercountry variations in
incidence rates and distribution of prevalent PCR ribotypes, with the
outbreak-related PCR ribotype 027 being detected in 5% (range: 0–26) of the
characterised isolates [2]. The surveillance period was limited to one month
and the representation of European hospitals was incomplete; however, this has
been the only European (comprising European Union (EU)/European Economic Area
(EEA) and EU candidate countries) CDI surveillance study. The authors
highlighted the need for national and European surveillance to control CDI.
Yet, European countries were found to have limited capacity for diagnostic
testing, particularly in terms of standard use of optimal methods and absence
of surveillance protocols and a fully validated, standardised and exchangeable
typing system for surveillance and/or outbreak investigation. As of 2011, 14
European countries had implemented national CDI surveillance, with various
methodologies [3]. National surveillance systems have since reported a
decrease in CDI incidence rate and/or prevalence of PCR ribotype 027 in some
European countries [4-8]. However, CDI generally remains poorly controlled in
Europe [9], and PCR ribotype 027 continues to spread in eastern Europe [10-12]
and globally [13]. In 2010, ECDC launched a new project, the European C.
difficile Infection Surveillance Network (ECDIS-Net), to enhance surveillance
of CDI and laboratory capacity to test for CDI in Europe. The goal of ECDIS-
Net was to establish a standardised CDI surveillance protocol suitable for
application all over Europe in order to: (i) estimate the incidence rate and
total infection rate of CDI (including recurrent CDI cases) in European acute
care hospitals; (ii) provide participating hospitals with a standardised tool
to measure and compare their own incidence rates with those observed in other
participating hospitals; (iii) assess adverse outcomes of CDI such as
complications and death; and (iv) describe the epidemiology of CDI concerning
antibiotic susceptibility, PCR ribotypes, presence of tcdA, tcdB and binary
toxins and detect new emerging types at local, national and European level.
The primary objectives of the present study were to: (i) test the pilot
protocol for the surveillance of CDI in European acute care hospitals
developed by ECDIS-Net (methodology, variables and indicators); (ii) assess
the feasibility and workload of collecting the required hospital data, case-
based epidemiological and microbiological data; and (iii) evaluate the quality
of data collected, whether in the presence or absence of existing national CDI
surveillance activities. A secondary aim was to assess the relationship
between patient and microbiological characteristics and in-hospital outcome of
CDI to confirm the added value of collecting detailed epidemiological and
microbiological data on CDI at European level
Standardised surveillance of Clostridium Difficile Infection in European acute care hospitals: A pilot study, 2013
Clostridium difficile infection (CDI) remains poorly controlled in many European countries, of which several have not yet implemented national CDI surveillance. In 2013, experts from the European CDI Surveillance Network project and from the European Centre for Disease Prevention and Control developed a protocol with three options of CDI surveillance for acute care hospitals: a ‘minimal’ option (aggregated hospital data), a ‘light’ option (including patient data for CDI cases) and an ‘enhanced’ option (including microbiological data on the first 10 CDI episodes per hospital). A total of 37 hospitals in 14 European countries tested these options for a three-month period (between 13 May and 1 November 2013). All 37 hospitals successfully completed the minimal surveillance option (for 1,152 patients). Clinical data were submitted for 94% (1,078/1,152) of the patients in the light option; information on CDI origin and outcome was complete for 94% (1,016/1,078) and 98% (294/300) of the patients in the light and enhanced options, respectively. The workload of the options was 1.1, 2.0 and 3.0 person-days per 10,000 hospital discharges, respectively. Enhanced surveillance was tested and was successful in 32 of the hospitals, showing that C. difficile PCR ribotype 027 was predominant (30% (79/267)). This study showed that standardised multicountry surveillance, with the option of integrating clinical and molecular data, is a feasible strategy for monitoring CDI in Europe
Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease
The prevalence of Clostridium difficile infection (CDI) in pediatric patients with inflammatory bowel disease (IBD) is still not sufficiently recognized. We assessed the prevalence of CDI and recurrences in outpatients with IBD. In addition, the influence of IBD therapy on CDI and antimicrobial susceptibility of the potentially causative C. difficile strains was assessed. This was a prospective, single-center, observational study. All specimens were obtained between January 2005 and January 2007 from the IBD outpatient service and screened for C. difficile and its toxins. C. difficile isolates were genotyped by PCR ribotyping. Diagnosis of Crohn’s disease (CD) and ulcerative colitis (UC) was based on Porto criteria. Severity of disease was assessed using the Hyams scale (for Crohn’s disease) and the Truelove–Witts scale (for ulcerative colitis). One hundred and forty-three fecal samples from 58 pediatric IBD patients (21 with Crohn’s disease and 37 with ulcerative colitis) were screened. The risk of C. difficile infection was 60% and was independent of disease type (CD or UC) (χ2 = 2.5821, df = 3, p = 0.4606). About 17% of pediatric IBD patients experienced a recurrence of CDI. All C. difficile strains were susceptible to metronidazole, vancomycin and rifampin. A high prevalence of C. difficile infection and recurrences in pediatric outpatients with IBD was observed, independent of disease type. There was no significant correlation between C. difficile infection and IBD therapy. PCR ribotyping revealed C. difficile re-infection and relapses during episodes of IBD in pediatric outpatients
Steroid-refractory ulcerative colitis treated with corticosteroids, metronidazole and vancomycin: a case report
BACKGROUND: Increasing evidence elucidating the pathogenic mechanisms of ulcerative colitis (UC) has accumulated and the disease is widely assumed to be the consequence of genetic susceptibility and an abnormal immune response to commensal bacteria. However evidence regarding an infectious etiology in UC remains elusive. CASE PRESENTATION: We report a provocative case of UC with profound rheumatologic involvement directly preceded by Clostridium difficile infection and accompanying fever, vomiting, bloody diarrhea, and arthritis. Colonic biopsy revealed a histopathology suggestive of UC. Antibiotic treatment eliminated detectable levels of enteric pathogens but did not abate symptoms. Resolution of symptoms was procurable with oral prednisone, but tapering of corticosteroids was only achievable in combination therapy with vancomycin and metronidazole. CONCLUSIONS: An infectious pathogen may have both precipitated and exacerbated autoimmune disease attributes in UC, symptoms of which could be resolved only with a combination of corticosteroids, vancomycin and metronidazole. This may warrant the need for more perceptive scrutiny of C. difficile and the like in patients with UC
- …